SBI Securities’s Esperion Therapeutics ESPR Stock Holding History

SBI Securities’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.37K	Hold	433	–	–	﹤0.01%	2689
2026 Q1	$1.19K	Sell	433 -1,000	-70%	-$3.17K	﹤0.01%	2597
2025 Q4	$5.3K	Buy	1,433 +5	+0.4%	+$16	﹤0.01%	1991
2025 Q3	$3.78K	Buy	1,428 +1	+0.1%	+$2	﹤0.01%	2163
2025 Q2	$1.41K	Buy	1,427 +684	+92%	+$685	﹤0.01%	2534
2025 Q1	$1.07K	Sell	743 -60	-7%	-$111	﹤0.01%	2549
2024 Q4	$1.77K	Buy	+803	New	+$1.87K	﹤0.01%	2362

Other funds holding ESPR

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

SBI Securities's ESPR Position: Q2 2026 in Review

SBI Securities held its Esperion Therapeutics (ESPR) position steady in Q2 2026 at 433 shares worth $1.37K. The position accounts for ﹤0.01% of the portfolio, ranked #2689.

SBI Securities first reported a position in ESPR in Q4 2024 and has held it in 7 quarters since. The position peaked at $5.3K in Q4 2025. 192 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

SBI Securities held 433 shares of Esperion Therapeutics worth $1.37K as of Q2 2026.
SBI Securities left its Esperion Therapeutics share count unchanged in Q2 2026.
Esperion Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #2689 holding.
SBI Securities first reported a position in Esperion Therapeutics in Q4 2024 and has held it in 7 quarters since.
SBI Securities's Esperion Therapeutics position peaked at $5.3K in Q4 2025.
192 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.